Edwards Lifesciences (EW) PT Raised to $89 at Canaccord Genuity

Canaccord Genuity analyst William Plovanic raised the price target on Edwards Lifesciences (NYSE: EW) to $89.00 (from $84.00) while maintaining a Hold rating.

The analyst comments "Bottom line: Edwards hosted its annual investor day, where the company gave its initial guidance for 2026 and provided updates on its broad pipeline. We believe that the company set guidance that is, at a minimum, achievable. EW’s bottom-line growth continues to outpace the top line as the company continues to find leverage opportunities, while still investing a significant amount in R&D. We believe that the company’s catalysts for 2026 could provide future growth inflections – but most are weighted toward the 2H/26 – so upside to 2026 numbers will mostly rely on better-than-expected execution. We continue to warm up to the name, given that we believe the tide has turned due to there being more tailwinds than headwinds, but are maintaining our HOLD rating given expectations for a back-end-loaded 2026. We are adjusting our PT to $89 from $84."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Freedom Broker Upgrades Lifeway Foods (LWAY) to Buy
• Home Depot (HD) call put ratio 1.5 calls to 1 put with a focus on September 330 puts into quarter results